New hope for cervical cancer when standard immunotherapy fails
NCT ID NCT07186868
Summary
This study is for women whose advanced cervical cancer has gotten worse after treatment with a common type of immunotherapy (PD-1/PD-L1 drugs). Researchers want to see if a new combination of two immunotherapy drugs plus chemotherapy, with or without an anti-blood-vessel drug, can help control the cancer. About 25 women will receive the treatment and be monitored to see if their tumors shrink, how long the benefit lasts, and how they feel.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.